Abbott Laboratories has agreed to a significant settlement to resolve legal challenges arising from the 2022 closure of its major baby formula production facility. This agreement addresses a Justice Department lawsuit and claims brought by various state attorneys general, marking a resolution to the events that severely impacted the nation's infant formula supply. Despite the financial settlement, Abbott asserts that this resolution does not signify an admission of fault or liability on its part.
Abbott Reaches $385 Million Agreement Following Infant Formula Factory Incident
In September 2026, Abbott Laboratories, a prominent healthcare company, finalized a $385 million agreement. This settlement aims to resolve claims linked to a comprehensive investigation into potential contamination at its Sturgis, Michigan baby formula manufacturing plant, the largest of its kind in the United States. The initial closure of this facility in February 2022, following an investigation by the Food and Drug Administration, led to a substantial recall of powdered infant formula products, including popular brands like Similac. This recall exacerbated an already strained supply chain, partly due to disruptions from the Covid-19 pandemic and increased stockpiling. The incident prompted a lawsuit from the Justice Department and legal actions from multiple state attorneys general. Abbott has consistently maintained that subsequent tests by government regulators on unopened product from the homes of affected infants showed no presence of Cronobacter sakazakii, a bacterium capable of causing severe illness in infants. Furthermore, the company stated that no unopened, distributed Abbott infant formulas have ever tested positive for the bacterium. The facility was able to resume operations by June of the same year, and a previous criminal investigation into the matter, initiated under the Trump administration, was closed. In response to the crisis, the Biden administration implemented measures such as easing import restrictions for foreign manufacturers, airlifting formula from Europe, and invoking federal emergency rules to prioritize domestic production.
This resolution underscores the critical importance of robust quality control and regulatory oversight within the infant formula industry. It highlights the far-reaching consequences that production disruptions at a single major facility can have on a national scale, impacting vulnerable populations. The incident also shed light on the fragility of supply chains in times of crisis and the need for agile governmental responses to safeguard public health and consumer access to essential goods. For manufacturers, it serves as a stark reminder of the immense responsibility in ensuring product safety and maintaining consumer trust, even as they navigate complex legal and public relations challenges.